All News
ICYMI: Psoriatic Arthritis and Pregnancy
Dr. Christina Chambers, an epidemiologist at the University of California San Diego and the principal investigator of MotherToBaby Pregnancy Studies, reviewed the available data on psoriatic arthritis and pregnancy. There is little evidence at this time that pregnancy affects PsA, though studies reliably demonstrate increase in disease activity in the post-partum period in both skin and joint disease.
Read Article
One in Ten has Autoimmune Disease
A UK population-based study suggests that autoimmune diseases affect approximately one in ten individuals.
Read Article
Downs Syndrome (1/700) & autoimmune mechanisms - Downs has a 4-6 fold higher risk of JIA, type 1 diabetes, autoimmune thyroid disease and coeliac disease. https://t.co/wVUDRCS96I https://t.co/RosPAkRnPA
Dr. John Cush RheumNow ( View Tweet)
Thanks to these Rheumatology Influencers who were tweeting & teaching from RheumNow Live 2023!
Look for all the RNL23 Replays this month- videos, podcasts, articles, & tweets
@ericdeinmd @doctorRBC @NoufAhmedAlham2 @Janetbirdope @uptoTate @anisha_dua @DrLauraCoates https://t.co/AgvQ06dp3Z
Dr. John Cush RheumNow ( View Tweet)
in 2022 COVID slid from the #3 to the #4 cause of death in USA, accounting for nearly a quarter million deaths, a 47 percent decrease from the 462,193 Covid-related deaths in 2021. Most COVID deaths occured in the first few mos of 2022 https://t.co/qervCp0P87 https://t.co/WN7DvsFhNC
Links:
Dr. John Cush RheumNow ( View Tweet)
Does King Charles have Sausage Digits (dactylitis) or OA? https://t.co/mRis21OWKH https://t.co/mRis21OWKH https://t.co/TmPDKu6ARh
Dr. John Cush RheumNow ( View Tweet)
Prevalence and Mortality of IgG4-related disease in the USA
A review of the epidemiology of IgG4-RD in the USA shows a low prevalence with possibly increasing numbers, owing to increasing awareness of this unique immune-mediated condition.
https://t.co/umWCPX4ing https://t.co/ZIButYrtp0
Links:
Dr. John Cush RheumNow ( View Tweet)
Romosuzumab and Low Sclerostin Levels Underlie CV Risk
New research highlights potential safety concerns around women taking romosozumab, a new anti-osteoporosis drug available on the NHS.
https://t.co/tRGOXrm0Fk https://t.co/ebiRpCC81p
Links:
Dr. John Cush RheumNow ( View Tweet)
Contratulations to Dr Germain Honvo (Univ. of Abomey-Calavi, Univ. Liège/Belgium) in receiving the 2023 Pierre Meunier Young Scientist Award from ESCEO & the International Osteoporosis Foundation (IOF) for his work in osteoarthritis, aging & locomotion https://t.co/gOB6VfP9vn https://t.co/SBbexkty4F
Links:
Dr. John Cush RheumNow ( View Tweet)
Clinical overview of subacromial pain syndr (SAPS) Brit J Sports Med. SAPS has heterogeneous causes; Dx by physical examination and imaging. Need to exclude glenohumeral OA, frozen shoulder, GH instability, rotator cuff tears, neuro & cervical disorders https://t.co/d77kXa2qSi https://t.co/vBF0692huh
Links:
Dr. John Cush RheumNow ( View Tweet)
DDW 2023 study claims microscopic colitis (MC) pts had a 2fold higher risk of #RA. 11,293 MC pts matched 1:5 w/ population controls. With 8 yrs of F/U, RA was found in 1.1% of MC vs 0.6% controls (adj HR 1.92 (95% CI = 1.56-2.34). https://t.co/R5faYDoaAq https://t.co/qiaOMgOyLR
Links:
Dr. John Cush RheumNow ( View Tweet)
REMIT-UC: Tofacitinib study 334 w/ Ulcerative Colitis:Clinical remission in 35%, Endoscopic remission in ~24%; & low risk (per/100PY) of serious infections (2.1), H zoster (0.5), & VTE (1.1). Loss of response in 45%, but recaptured 55% w/ dose escalation https://t.co/OgQYcq9pQk https://t.co/1KtLDvkQGT
Links:
Dr. John Cush RheumNow ( View Tweet)
BMJ Systematic review of OP trials (69 RCTs, >80k pts) & Fx rates in postmenopausal F shows protective effect of bisphosphonates, PTH receptor agonists, & romosozumab vs PBO. Most effective PTHra > ROMO > Denosumab > bisphosphonates > PBO https://t.co/wKVCUnjmNT MJ
Links:
Dr. John Cush RheumNow ( View Tweet)
715 women w/ infertility from recurrent implantation failure were randomized to either placebo or prednisone 10 mg/d. Live birth rates were unaffected by pred (37.8% 38.8% w/ PBO; NS), but pred did increase rate of preterm deliveries (11.8% vs 5.5%; P=.04) https://t.co/ey5JDk2Xi5 https://t.co/Rcgphj147r
Links:
Dr. John Cush RheumNow ( View Tweet)
Treatment and Management of Neuropsychiatric Lupus
On the first day of ACR State of the Art conference in Orlando, Florida, Dr. Michelle Petri reviewed the treatment and management of neuropsychiatric lupus.
https://t.co/99GXxyIjLl https://t.co/Bor7R2qVtN
Links:
Dr. John Cush RheumNow ( View Tweet)
Stop RA trail:
Plaquenil didn’t prevent RA in patient with pre clinical RA. Kevin Deane #RNL2023 @RheumNow https://t.co/gO9QKbAues https://t.co/gEpuBvDpj5
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2023 @RheumNow
There are a lot of RA Rx on market now - do we need more?
Dr. Brenner: YES
Stromal targets like LIF/LIFR, Notch3, cadherin-11 offer upstream benefits for our difficult to treat RA patients that don't respond to tradition cs/bDMARDs https://t.co/Og1vvbTRO9 https://t.co/WyqPH0lgkd
Links:
Dr. John Cush RheumNow ( View Tweet)
JAKinib safety takeaways
- avoid in older population 65 yo, malignancy, CV risk, VTE risk
- appropriate in younger pts without VTE/CVD risk factors
#RNL2023 @RheumNow https://t.co/mFvvqJ9Jbp https://t.co/A76tR2S1Rb
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2023 @RheumNow
Dr. Stanley Cohen: possible adverse effects of JAKi
-Herpes zoster, other infections
-Malignancy
-Occasional cytopenias
-LFTs (with DMARDs)
-Incr Cr or CPK
-Acne
-Incr lipids
-GI perf
-VTE
Which do you counsel with your patients? https://t.co/zncCw3jlK7 https://t.co/AHhDyxaumM
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Stanley Cohen on JAKinibs:
Very concise and informative timeline on the multiple JAKinibs approved for multiple conditions
@RheumNow #RNL2023 https://t.co/ulLh2HikUt https://t.co/0kR8CNZvsV
Links:
Dr. John Cush RheumNow ( View Tweet)
